By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MicroRNA-based technology startup Firefly BioWorks has raised about $2 million in a private financing, which it plans to use to test its platform directed at cancer-related research.

Firefly co-founder and CEO Davide Marini, told GenomeWeb Daily News that the company plans to test the product with a select group of researchers to assess its utility but declined to provide further details. He also declined to identify investors in the round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."

Sep
10
Sponsored by
Qiagen

In this online seminar, Jo Vandesompele of the Center for Medical Genetics at Ghent University will discuss methods for improving the analysis of microRNA expression from a range of samples.